You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》雅培(ABT.US)季績勝預期 料年初錄25億美元新冠檢測銷售
阿思達克 01-27 10:31
美國藥廠雅培實驗室(ABT.US)公佈去年第四季業績。季度純利19.89億美元,按年跌8%。每股季度攤薄純利1.11美元,經調整後爲1.32美元,高於市場預期的1.21美元。季度淨銷售114.68億美元,按年升7.2%,高於市場預期的107億美元。 新冠檢測產品上季銷售23億美元,略低於2020年同期的24億美元。公司預期今年初將錄得25億美元相關銷售,高於早前預期首季度10億至14億美元的預測。公司預期現財年經調整每股純利最少4.7美元,市場預期爲4.78美元。 雅培股價昨日(26日)跌2.6%,報120.07美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account